Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer PR Newswire LUND, Sweden, Feb. 22, 2024 LUND, Sweden , Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024 . He succeeds Donato Spota , who, as previously announced, will leave the Company on 28 February. As CFO, Mr. Ballantyne will be responsible for developing and implementing the Company's...